Aptus Pharma H1 Revenue Surges 240% to ₹48.92 Crore

APTUS PHARMA LIMITED

Financial Performance Highlights (H1 FY27)

Income Statement (₹ in Lakhs):

• Revenue from operations: ₹4,892.04 (vs. ₹1,437.75 in H1 FY26 - 240% increase)
• Other income: ₹3.60
• Total income: ₹4,895.64
• Cost of materials consumed: Not separately disclosed
• Purchase of stock-in-trade: ₹3,080.93
• Changes in inventories: (₹268.42) decrease
• Employee benefit cost: ₹399.69
• Finance cost: ₹75.30
• Depreciation and amortization: ₹34.61
• Other expenses: ₹890.87
• Profit before tax: ₹682.66 (vs. ₹235.11 in H1 FY26)
• Tax expense: ₹175.00 (Current) + (₹0.95) (Deferred)
• Net profit: ₹507.66 (vs. ₹174.69 in H1 FY26)
• Basic EPS: ₹2.96 (not annualized)
• Diluted EPS: ₹2.96 (not annualized)

Balance Sheet (₹ in Lakhs as at 30/09/2026):

• Share capital: ₹1,715.00 (increased from ₹686.00 as at 31/03/2026)
• Reserves & surplus: ₹1,127.27 (decreased from ₹1,648.62)
• Long-term borrowings: ₹704.27 (increased from ₹52.16)
• Short-term borrowings: ₹506.84 (decreased from ₹666.00)
• Trade payables to micro/small enterprises: ₹767.82
• Trade payables to other creditors: ₹145.77
• Inventories: ₹1,625.30
• Trade receivables: ₹2,864.23
• Cash and cash equivalents: ₹180.18
• Total assets: ₹5,455.43

Revenue Mix Analysis:

• Acute Therapy: ~44% of revenue
• Chronic & Semi-Chronic Therapy: ~20% of revenue
• Wellness & OTC Products: ~20% of revenue
• Sales of Service: ~16% of revenue

Corporate Actions

Preferential Issue:

• Members approved issuance of 16,02,870 equity shares of face value ₹10 each at issue price of ₹280 (including premium of ₹270)
• Total issue size: ₹44,88,03,600
• Subject to receipt of regulatory and statutory approvals
• Application submitted to BSE Limited for in-principle approval (under process)
• No share application money received or shares allotted as of 20th October 2026

Bonus Issue:

• In May 2026, company issued 102.90 lakh bonus equity shares in ratio of 3:2
• Resulting in total 171.50 lakh outstanding equity shares
• EPS figures restated retrospectively for comparison

Business Operations

Business Verticals:

1. Pharma Formulation: Core revenue through prescription-based branded generics

2. Consumer Products: OTC, wellness, personal-care through traditional trade and proposed e-commerce/D2C platform

3. International Business: Export services and merchant export facilitation

Operational Metrics:

• 300+ formulations portfolio
• 250+ distributors and sub-distributors
• 10,000+ doctor relationships
• 150+ industry professionals
• 50,000+ prescriptions daily
• 10+ contract manufacturing agreements
• Loan licence manufacturing facilities in Gujarat
• NABL accredited associate lab

Manufacturing Model:

• Asset-light contract manufacturing with WHO-GMP certified units
• Formal loan and licence agreements with two manufacturing units in Gujarat
• Additional products through other WHO-GMP compliant partners

Management Team

• Mr. Tejash M. Hathi: Managing Director (DIN: 03151221)
• Mr. Ghanshyam V. Pansuriya: Chief Executive Officer
• Mr. Kapil H. Chandarana: Chief Financial Officer
• Mr. Nirav J. Pandya: Vice President-Pan-India Operations
• Mr. Riddhish N. Tanna: Non-Executive Director
• Dr. Jyotiben H. Chandarana: Director (DIN: 10607059)
• Mr. Vikas R. Jobanputra: Independent Director
• CS Mohini H. Gandhi: Company Secretary & Compliance Officer

Strategic Initiatives

Expansion Targets:

• Target 46% geographic coverage across India by March 2027
• Global expansion into Uganda, Tanzania, Somalia, Malawi by March 2028
• Manufacturing expansion targeting 20% own manufacturing capacity
• Evolution into integrated pharmaceutical manufacturing and export-focused company

Quality Assurance:

• Stringent quality evaluation for every batch
• Tests include: API assay, dissolution/disintegration profile, uniformity of content, related substances compliance, impurity profiling, hardness test, pH evaluation, microbiological analysis, friability testing, Karl Fischer test, DEG and EG test